Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor

International Journal of Cancer

Volumn 120, Issue 10, 2007, Pages 2086-2095

  Nielsen, Boye S ^a   Rank, Fritz ^b   Illemann, Martin ^a   Lund, Leif R ^a   Danø, Keld ^a  

^a FINSEN LABORATORY   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Breast cancer; DCIS; Microinvasion; uPA; uPAR

Indexed keywords

COLLAGENASE 3; MESSENGER RNA; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; BASEMENT MEMBRANE; BREAST CARCINOMA; CANCER INVASION; CARCINOMA IN SITU; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN SITU HYBRIDIZATION; INTRADUCTAL CARCINOMA; MACROPHAGE; MYOFIBROBLAST; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; STROMA CELL;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; MATRIX METALLOPROTEINASE 13; RECEPTORS, CELL SURFACE; RNA, MESSENGER; STROMAL CELLS; URINARY PLASMINOGEN ACTIVATOR;

EID: 34147191467     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22340     Document Type: Article

References (46)

1. Sakorafas GH, Farley DR. Optimal management of ductal carcinoma in situ of the breast. Surg Oncol 2003;12:221-40.
2. de Mascarel I, MacGrogan G, Mathoulin-Pelissier S, Soubeyran I, Picot V, Coindre JM. Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer 2002;94:2134-42.
3. Nielsen BS, Rank F, Lopez JM, Balbin M, Vizoso F, Lund LR, Danø K, Lopez-Otin C. Collagenase-3 (MMP-13) expression in breast myofibroblasts as a molecular marker of transition of ductal caricnoma in situ lesions to invasive ductal carcinomas. Cancer Res 2001;61:7091-100.
4. Bugge TH, Kombrinck KW, Rick MJ, Daugherty CC, Danton MJ, Degen JL. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 1996;87:709-19.
5. Chen ZL, Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 1997;91: 917-25.
6. Cowell S, Knauper V, Stewart ML, D'Ortho MP, Stanton H, Hembry RM, Lopez-Otin C, Reynolds JJ, Murphy G. Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase. Biochem J 1998;331(Pt 2):453-8.
7. Danø K, Rømer J, Nielsen BS, Bjørn SF, Pyke C, Rygaard J, Lund LR. Cancer invasion and tissue remodeling - cooperation of protease systems and cell types. APMIS 1999;107:120-7.
8. Rømer J, Nielsen BS, Ploug M. The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des 2004;10:2359-76.
9. Llinas P, Le Du MH, Gardsvoll H, Dano K, Ploug M, Gilquin B, Stura EA, Menez A. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J 2005; 24:1655-63.
10. Huai Q, Mazar AP, Kuo A, Parry GC, Shaw DE, Callahan J, Li Y, Yuan C, Bian C, Chen L, Furie B, Furie BC et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science 2006;311:656-9.
11. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990;50:6827-9.
12. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993;53:2513-21.
13. Grøndahl-Hansen J, Peters HA, van Putten WLJ, Look MP, Pappot H, Rønne E, Danø K, Klijn JGM, Brünner N, Foekens JA. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995;1:1079-87.
14. Nielsen BS, Sehested M, Timshel S, Pyke C, Danø K. Messenger RNA for urokinase plasminogen activator (uPA) is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 1996;74:168-77.
15. Nielsen BS, Sehested M, Rank F, Duun S, Timshel S, Rygaard J, Johnsen M, Danø K. Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab Invest 2001;81:1485-501.
16. Pyke C, Græm N, Ralfkiær E, Rønne E, Høyer-Hansen G, Brünner N, Danø K. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 1993;53:1911-15.
17. Offersen BV, Nielsen BS, Høyer-Hansen G, Rank F, Hamilton-Dutoit S, Overgaard J, Andreasen PA. The myofibroblast is the predominant plasminogen activator inhibitor-1 expressing cell type in human breast cancer. Am J Pathol 2003;163:1887-99.
18. Wolf C, Rouyer N, Lutz Y, Adida C, Loriot M, Bellocq JP, Chambon P, Basset P. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA 1993;90:1843-7.
19. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996;149:273-82.
20. Nielsen BS, Sehested M, Kjeldsen L, Borregaard N, Rygaard J, Danø K. Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab Invest 1997;77:345-55.
21. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:163-76.
22. Lynch CC, Matrisian LM. Matrix metalloproteinases in tumor-host cell communication. Differentiation 2002;70:561-73.
23. Durand MK, Bodker JS, Christensen A, Dupont DM, Hansen M, Jensen JK, Kjelgaard S, Mathiasen L, Pedersen KE, Skeldal S, Wind T, Andreasen PA. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost 2004;91:438-49.
24. Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M, Rømer J. Plasminogen activation and cancer. Thromb Haemost 2005;93:676-81.
25. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, Lewinsky B, Gamagami P, Slamon DJ. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995;345:1154-7.
26. Rønne E, Behrendt N, Ellis V, Ploug M, Danø K, Høyer-Hansen G. Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett 1991;288:233-6.
27. Rønne E, Høyer-Hansen G, Brünner N, Pedersen H, Rank F, Osborne CK, Clark GM, Danø K, Grøndahl-Hansen J. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat 1995;33:199-207.
28. Dickinson ME, Bearman G, Tilie S, Lansford R, Fraser SE. Multispectral imaging and linear unmixing add a whole new dimension to laser scanning fluorescence microscopy. Biotechniques 2001;31: 1272-8.
29. Pyke C, Kristensen P, Ralfkiær E, Grøndahl-Hansen J, Eriksen J, Blasi F, Danø K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991;138:1059-67.
30. National coordinating group for breast screening pathology. Pathology reporting in breast cancer screening. Sheffield: NHS BSP, 1995. 28 pp.
31. Bianchi E, Cohen RL, Thor AT, Todd RF, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA, Smith HS. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 1994;54:861-6.
32. Nakayama M, Yoshida E, Sugiki M, Anai K, Maruyama M, Mihara H. Up-regulation of the urokinase-type plasminogen activator receptor by monocyte chemotactic proteins. Blood Coagul Fibrinolysis 2002;13: 383-91.
33. Yoshida E, Tsuchiya K, Sugiki M, Sumi H, Mihara H, Maruyama M. Modulation of the receptor for urokinase-type plasminogen activator in macrophage-like U937 cells by inflammatory mediators. Inflammation 1996;20:319-26.
34. Simon DI, Rao NK, Xu H, Wei Y, Majdic O, Ronne E, Kobzik L, Chapman HA. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 1996;88: 3185-94.
35. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6:24-37.
36. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006; 124:823-35.
37. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-12.
38. Dubuisson L, Monvoisin A, Nielsen BS, Le Bail B, Bioulac-Sage P, Rosenbaum J. Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in hepatocellular carcinomas. J Pathol 2000;190:190-5.
39. Ohtani H, Pyke C, Danø K, Nagura H. Expression of urokinase receptor in various stromal-cell populations in human colon cancer: immunoelectron microscopical analysis. Int J Cancer 1995;62:691-6.
40. Hildenbrand R, Arens N. Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue. Br J Cancer 2004;91:564-71.
41. Hildenbrand R, Leitz M, Magdolen V, Luther T, Albrecht S, Graeff H, Stutte HJ, Bleyl U, Schmitt M. Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization. Histopathology 2000;36:499-504.
42. Almholt K, Lund LR, Rygaard J, Nielsen BS, Danø K, Rømer J, Johnsen M. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int J Cancer 2005;113:525-32.
43. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994;368:419-24.
44. Stickens D, Behonick DJ, Ortega N, Heyer B, Hartenstein B, Yu Y, Fosang AJ, Schorpp-Kistner M, Angel P, Werb Z. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development 2004;131:5883-95.
45. Lund LR, Rømer J, Bugge TH, Nielsen BS, Frandsen TL, Degen JL, Stephens R, Danø K. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J 1999;18:4645-56.
46. Solberg H, Rinkenberger J, Danø K, Werb Z, Lund LR. A functional overlap of plasminogen and MMPs regulates vascularization during placental development. Development 2003;130:4439-50.